Dr. Bret E. Friday

Essentia Health Cancer Center

Expert in Cancer
Expert in Lung Cancer
96 reported clinical trials
168 drugs studied
1 year of experience

About Bret E. Friday


  • Graduated with an MD from the University of Minnesota Medical School, Twin Cities Campus, in 2007.
  • Completed Residency in Radiation Oncology at the University of Minnesota Medical Center in 2012.
  • Undertook a Fellowship in Brachytherapy at the University of Minnesota Medical Center in 2013.


  • Board Certified in Radiation Oncology by the American Board of Radiology.
  • Has been practicing as a Radiation Oncologist at Essentia Health Cancer Center since 2013.

Area of expertise

Global Leader
Bret E. Friday has run 42 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Lung Cancer
Global Leader
Bret E. Friday has run 19 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Affiliated Hospitals

Image of trial facility.
Essentia Health Cancer Center
Image of trial facility.
Essentia Health Sandstone

Clinical Trials Bret E. Friday is currently running

Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Fulvestrant + Binimetinib

for Breast Cancer

This ComboMATCH phase II trial compares the usual treatment alone (fulvestrant) to using binimetinib plus the usual treatment in patients with hormone receptor positive breast cancer that has spread from where it first started to other places in the body (metastatic) and has an NF1 genetic change. Fulvestrant is a hormonal therapy that binds to estrogen receptors in tumor cells, resulting in estrogen receptor destruction and decreased estrogen binding, which may inhibit the growth of estrogen-sensitive tumor cells. Binimetinib is a targeted therapy that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of binimetinib to fulvestrant in breast cancers with an NF1 genetic change could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to fulvestrant alone.
Recruiting1 award Phase 219 criteria

More about Bret E. Friday

Clinical Trial Related1 year of experience running clinical trials · Led 96 trials as a Principal Investigator · 54 Active Clinical Trials
Treatments Bret E. Friday has experience with
  • Nivolumab
  • Fluorouracil
  • Paclitaxel
  • Pembrolizumab
  • Ipilimumab
  • Carboplatin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Bret E. Friday specialize in?
Bret E. Friday focuses on Cancer and Lung Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Bret E. Friday currently recruiting for clinical trials?
Yes, Bret E. Friday is currently recruiting for 48 clinical trials in Duluth Minnesota. If you're interested in participating, you should apply.
Are there any treatments that Bret E. Friday has studied deeply?
Yes, Bret E. Friday has studied treatments such as Nivolumab, Fluorouracil, Paclitaxel.
What is the best way to schedule an appointment with Bret E. Friday?
Apply for one of the trials that Bret E. Friday is conducting.
What is the office address of Bret E. Friday?
The office of Bret E. Friday is located at: Essentia Health Cancer Center, Duluth, Minnesota 55805 United States. This is the address for their practice at the Essentia Health Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.